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Dermal Microvasculature in Psoriasis 
To the Editor: 
Recently Braverman an d Sibley described their observations re-
garding the ultr.astructure of dermal capillaries and the labeling 
index of basal cells in psoriasis during different therapies [1]. The 
authors showed a lack of response of the dermal microvasculature 
to methotrexate and topical corticosteroids. During PUV A and 
Goeckerman treatment the same authors observed a prompt nor-
malization of the dermal microvasculature before the labeling 
index of the basal cell layer reverted to normal [2]. 
They concluded that normalization of microvasculature is re-
sponsible for the longer remission periods during the latter two 
therapies and that the fast relapses following discontinuation of 
methotrexate and corticosteroids are the consequence of incom-
plete treatment of the dermal capillaries. This implies that the 
changes of dermal capillaries are of significance for the patho-
genesis of psoriasis. We wish to congratulate Drs . Braverman 
and Sibley with this synthesis of ultramorphology, cell cycle ki-
netics, and clinical experience. 
Some years ago the Nijmegen group examined the dynamic 
aspects of the psoriatic lesion: initiation (response to standardized 
injury), progression (the margin zone of spreading psoriatic le-
sions) and therapeutic regression (PUV A, topical corticosteroids). 
We measured epidermal cell cycle kinetics and some marker en-
zymes, including acid phosphatase (keratinization), glucose-6-
phosphate dehydrogenase (epidermal proliferation), and alkaline 
phosphatase (capillaries). We reached the following conclusions: 
A. Following standardized skin injury the capillaries of psoriatic 
patients overreact in comparison with the epidermal parameters 
[3] . 
Fibronectin Receptor Function 
To the Editor: 
We have several questions for Drs. Takashima and Grinnell, whose 
recent article concerning epidermal outgrowth from explants [1] 
we read with great interest and benefit. 
A. Figure 1 is an experiment which shows that after 3 days, 
su bsequent epidermal migration is fibronectin dependent. Do the 
authors have any information on whether fibronectin plays a role 
in the initiation of migration from days 0-3? 
B. In the same experiment, 400 p,g/ml of antifibronectin an-
tibody or preimmune IgG was used. Is this not an excessive 
amount of protein to be adding? What is the approximate ratio 
of antifibronectin antibody molecules to fibronectin molecules? 
Could this large amount of protein be producing nonspecific 
effects? 
C. Since epidermal outgrowth after day 3 can be due to epi-
dermal cell mitosis [2], is there any information on whether fi-
bronectin affects the mitotic phase of epidermal outgrowth from 
explants? 
D . Figure 4 shows that by day 4, 80% of the keratinocytes in 
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B. In the margin zone of spreading psoriatic plaques the cap-
illaries are abnormal up to 1.2 cm outside the clinical boundary, 
whereas epidermal abnormalities are seen only 0.4 cm outside the 
clinical edge [4]. 
C. During PUV A therapy the parameters of the epidermis and 
capillaries normalize at the same speed. By contrast, corticoste-
roids have no response on the marker for capillaries [5]. 
We now may reach a synthesis in which molecular biology 
takes part as well. The capillary changes are rIOt an epiphenomenon 
in the pathogenesis of psoriasis, and normalization of capillaries 
is essential for sustained remissions . 
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cult:lre are basal cells. The authors hypothesize in the discussion 
that it is this increased pool of basal ceBs which exhibits fibro-
nectin receptor function. However, Figure 3 shows that on day 
4, approximately 5% of the cells attach. Do the authors think 
this is due to a lag in the expression of fibronectin receptor func-
tion? 
Overall, we found the paper of great interest and believe the 
results to be of great importance in understanding epidermal wound 
healing. 
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